Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
IL237644D0
Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AU2014364414A1
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
KR20160095161A
Process methods for phosphatidylinositol 3-kinase inhibitors
AU2013364068A1
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
TW201437203A
Phosphatidylinositol 3-kinase inhibitors
AU2013302617A1
Combination therapies for treating cancer
NZ629684A
Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
WO2013116562A1
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
WO2013082540A1
Compositions and methods of treating a proliferative disease with a quinazolinone derivative
CN104024257A
Novel quinoxaline inhibitors of PI3K
SG193337A1
Combination therapies for hematologic malignancies
EP2619209A1
Atropisomers of pi3k-inhibiting compounds
MX2012000817A
Treatment of liver disorders with pi3k inhibitors.
